Results 161 to 170 of about 138,072 (341)

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

British Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk, Geoffrey Chong, Richard Khor, Denise Lee, Sze Ting Lee, Andrew M. Scott, Anneke C. Grobler, Belinda A. Campbell, Thanuja Thachil, Kate Manos, Genevieve Douglas, Alexandra Romano, Jodie B. Palmer, Melinda Burgess, Colm Keane, Eliza A. Hawkes   +15 more
wiley   +1 more source

Results of chemotherapy by UKCCSG protocol in children with acute lymphoblastic leukemia: Clinical characteristics and outcome [PDF]

Background: Acute lymphoblastic leukemia (ALL) represents a clonal expansion and arrest of normal lymphoid hematopoiesis. ALL remains the most common malignancy in children.
فتحی, افشین, هیرادفر, امیر عطا ا..., پدرام, محمد   +2 more
core  

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

British Journal of Haematology, EarlyView.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler, Marion Malphettes, Véronique Meignin, David Boutboul, Lionel Galicier   +4 more
wiley   +1 more source

Splenomegaly

International Journal of Clinical Practice, 1955
openaire   +2 more sources

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

Cancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang   +15 more
wiley   +1 more source

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen, Hanadi El Achi, Levani Iashvili, Amer Wahed, Brenda Mai, Jacob Armstrong   +5 more
wiley   +1 more source

Venous thromboembolism related to cytomegalovirus infection: A case report and literature review [PDF]

, 2017
Farrell, John J, Jacob, Kavitha S, Kelkar, Amar H, Yousif, Eman B   +3 more
core   +2 more sources

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, EarlyView.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

A Collateral Venous Pathway in Omental Arch of Barkow After Spleen Preserving Distal Pancreatectomy

ANZ Journal of Surgery, EarlyView.
Cartanese Carmine, Scaramuzzi Matteo, De Luca Raffaele, Mastrandrea Giovanni, Sollitto Mario   +4 more
wiley   +1 more source

First‐Line Treatment of IGHV‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta, Enrica Antonia Martino, Danilo Lofaro, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito, Valter Gattei, Massimo Gentile   +13 more
wiley   +1 more source